News Releases May 09, 2023 New Assessment Scale to Measure Adherence to Oral Anticoagulants Based on Impact of Patient Relevant Bleeding in Atrial Fibrillation Presented at ISPOR 2023
News Releases January 03, 2023 First Patient Enrolled in Phase 3 Trial Evaluating Abelacimab in High-Risk Patients with Atrial Fibrillation Deemed Unsuitable for Current Anticoagulants
News Releases September 08, 2022 Anthos Therapeutics Announces that Abelacimab Has Received FDA Fast Track Designation for the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation
News Releases August 25, 2022 Anthos Therapeutics Launches Second Phase 3 Clinical Trial of Its Dual-acting Factor XI Inhibitor, Abelacimab
News Releases July 13, 2022 Four New Sets of Pre-Clinical Data Further Expands the Evidence Supporting Abelacimab
News Releases July 11, 2022 Anthos Therapeutics Announces that Abelacimab has Received FDA Fast Track Designation for the Treatment of Thrombosis Associated with Cancer
News Releases June 13, 2022 Anthos Therapeutics to Host Discussion with Global Experts on the Promise of Factor XI Inhibition at the 2022 BIO International Convention
News Releases May 26, 2022 Anthos Therapeutics Appoints Drew Young as Chief Commercial Officer and Head of Patient Experience
News Releases May 05, 2022 Abelacimab: First Factor XI Inhibitor to Enroll Patients in a Phase 3 Clinical Trial
News Releases January 05, 2022 Anthos Therapeutics Appoints David McIntyre as Chief Financial Officer
News Releases December 07, 2021 Atrial Fibrillation Clinical Trial with Novel Dual Activity Factor XI Agent Completes Enrollment
News Releases July 19, 2021 Anthos Therapeutics’ novel Factor XI inhibitor abelacimab significantly outperforms standard of care enoxaparin in prospective Phase 2 efficacy research published today in the New England Journal of Medicine
News Releases July 06, 2021 Blackstone Life Sciences and Novartis Create Anthos Therapeutics to Develop Innovative Targeted Medicines for Cardiovascular Disease